ClinicalTrials.gg
CompletedNCT00248040Updated Jan 10, 2024Results posted

Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

A Phase 2 interventional study of Reparixin continuous infusion and reparixin intermittent infusion in Ischemia-Reperfusion Injury and Kidney Diseases, sponsored by Dompé Farmaceutici S.p.A. Completed at 9 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-10.

Sponsored by Dompé Farmaceutici S.p.A · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies in Reperfusion Injury with a site in Italy — 4 open to participants now, 4 under way, none of them phase 3. Reperfusion Injury · Italy.

Enrollment
5th of 10
80 · median 60
Started
2005
the only one that year
Phase 2
2 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
1 of 11
Dompé Farmaceutici S.p.A

Among the 11 studies in Reperfusion Injury with a site in Italy, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2005, is one of 2 in phase 2, and was the 1st registered.

Reperfusion Injury

260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.

Browse Reperfusion Injury studies →

Open to participants now

4 of the 11 studies in Reperfusion Injury with a site in Italy are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 28 Reperfusion Injury studies recruiting now, 16 (57%) set no upper age limit and 7 (25%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Reperfusion Injury with a site in Italy, or all of them as a file.
02

Study summary

The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8. This study is configured to explore the safety and efficacy of reparixin in preventing the delayed graft function (DGF) after kidney transplantation.

Read the detailed description

Delayed graft function (DGF) is the most common allograft complication in the immediate kidney post-transplant period, affecting 25-35% of all patients who receive a cadaver graft, but rates up to 50% have been reported, especially in recipients of kidneys from marginal donors. It is an important clinical complication as it requires dialysis, prolongs hospitalisation, raises the cost of transplantation, and makes more difficult the management of immunosuppressive therapy. Although the effects of DGF on long-term graft function are still debated, there is overall increasing evidence that DGF reduces long-term graft survival. Moreover, given the well documented impact of acute rejection on long-term graft survival, it is conceivable that DGF and acute rejection synergize in negatively influencing long-term graft survival. Kidney reperfusion, after long cold ischemia period, is associated with an inflammatory reaction characterized by massive polymorphonuclear leukocyte (PMN) infiltration both at the glomerular and tubular levels. The importance of CXCL8 in recruiting PMN in kidney tissue during the ischemic time and after reperfusion has been clearly documented.

The efficacy of reparixin in preventing PMN infiltration and tissue damage in rat models of kidney transplantation and lung transplantation, as well as the safety shown in human phase 1 studies, provide the rationale for a clinical study aimed at evaluating the effect of reparixin in preventing DGF after kidney transplantation

03

Conditions studied

  • Ischemia-Reperfusion Injury
  • Kidney Diseases

Keywords

  • Kidney transplantation
  • Reperfusion Injury
  • Survival
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients accepted and listed for renal transplantation due to end stage renal disease (ESRD)
  • Planned isolated single kidney transplant from a non-living donor with brain death
  • Recipients of a kidney maintained in cold storage
  • Recipients at risk of developing DGF
  • Planned induction with + mycophenolate mofetil (MMF) or mycophenolic acid + biological induction
  • Patient willing and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations
  • Patient given written , prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care

Exclusion criteria

Exclusion Criteria:

  • Recipients of an intended multiple organ transplant
  • Recipients of a kidney from a living donor
  • Recipients of a kidney from a non-heart beating donor
  • Recipients of double kidney transplant
  • Re-transplant >2
  • Recipients of a kidney maintained by pulsatile machine perfusion
  • Concurrent sepsis
  • Recipients with hepatic dysfunction at the time of transplant
  • Clinical to central line access, or arteriovenous fistula, if any, not suitable for infusion of product
  • to non steroidal anti-inflammatory drugs (NSAIDs)
  • Patients simultaneously participating in any other clinical trials involving an investigational drug not yet authorized for use in kidney transplant
  • Pregnant or breast-feeding women
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    reparixin group - continuous infusion

    Continuous iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump. A dose of 2.772 mg/kg/h was administered for12 hours.

    Drug: Reparixin continuous infusion

  • Experimental
    reparixin group - intermittent infusion

    Intermittent iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump. A dose of 2.244 mg/kg was administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were administered over a total period of 22.5 hours.

    Drug: reparixin intermittent infusion

  • Placebo comparator
    placebo infusion

    Continuous/intermittent iv infusion of a volume/schedule matched saline into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.

    Other: placebo infusion

Interventions

  • The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.

    Also known as: REP

  • A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.

    Also known as: REP

  • Otherplacebo infusion

    placebo was volume/schedule matched saline

06

What researchers measure

Primary outcomes

  1. Creatinine Clearance (CrCl) in the Immediate Post-transplant Period

    CrCl was determined by two 60 minute urine collections, during the time intervals 1-3 and 10-12 hours of allograft reperfusion. Blood was withdrawn at the midpoint of each urine collection. CrCl at each timepoint was calculated according to the formula: creatinine clearance (mL/minutes) = urine creatinine (mmol/L) x urine volume (mL) / serum creatinine (mmol/L) x time of collection (minutes) An average was to be calculated from the two 60 minute values in each interval.

    Time frame: 1-3 and 10-12 hours post allograft reperfusion

Secondary outcomes

  1. Renal Function Tests - Serum Creatinine

    Serum creatinine (SrCr) was measured daily from Day 1 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier; in patients undergoing dialysis, SrCr values were measured immediately before dialysis.

    Time frame: daily up to day 7 post-transplant or hospital discharge

  2. Renal Function Tests - Calculated Glomerular Filtration Rate

    Calculated glomerular filtration rate (GFR) was measured daily from Day 1 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier; in patients undergoing dialysis, SrCr values were measured immediately before dialysis

    Time frame: from Day 1 up to 7 days post-transplant or up to hospital discharge

  3. Renal Function Tests - Urine Output

    Urine output, measured in the interval from transplant to 8:00 of Day 1, and then daily from Day 2 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier

    Time frame: from Day 1 up to 7 days post-transplant or up to hospital discharge

  4. Number of Patients Requiring Dialysis Within 7 Days Post-transplant

    The number of patients who required dialysis within 7 days post-transplant was evaluated.

    Time frame: up to day 7 post-transplant

  5. Number of Days on Dialysis Before Resuming Kidney Function

    the number of days on dialysis before resuming kidney function was evaluated.

    Time frame: up to Day 7 post-transplant

  6. Number of Patients With Immediate, Slow and Delayed Graft Function

    The number of patients who required dialysis within 7 days post-transplant was evaluated. Immediate graft function: SrCr ≤3 mg/dL on post operative day 5) Slow graft function: SrCr \>3 mg/dL dL on post operative day 5, no need of dialysis) Delayed graft function: Dialysis needed in the first week)

    Time frame: day 5 post-transplant

  7. Duration of Hospital Stay

    The mean duration of hospital stay was evaluated.

    Time frame: first 30 days post-transplant

  8. Mortality

    Mortality in the first 30 days post-transplant was evaluated.

    Time frame: first 30 days post-transplant

  9. Serum Creatinine at Month 1, Month 6 and Month 12

    Serum creatinine (SrCr) was measured at Month 1, Month 6 and Month 12.

    Time frame: at Month 1, Month 6 and Month 12

  10. Calculated Serum Creatinine Clearance at Month 1, Month 6 and Month 12

    Creatinine clearance (CrCl) is the volume of blood plasma cleared of creatinine per unit time. It is a rapid and cost-effective method for the measurement of renal function.

    Time frame: at Month 1, Month 6 and Month 12

  11. Acute Rejection Episodes at Month 6 and Between Month 6 and Month 12

    Acute rejection defined as an increase in serum creatinine level after exclusion of other causes of graft dysfunction, accompanied by a sudden decline in glomerular filtration rate and renal function and well-established diagnostic features on kidney allograft biopsy which can be either antibody-mediated and/or T cell-mediated and can occur at any time after transplant.

    Time frame: at Month 6 and between Month 6 and Month 12

  12. Patient Survival Rate

    Numbers of patients alive, dead, and lost to follow up are reported.

    Time frame: at Month 1, Month 6 and Month 12

  13. Graft Survival Rate

    Graft failure was defined as the failure of graft function for any reason, ultimately requiring renal replacement therapy and/or retransplantation (United States Renal Data System \[USRDS\] 2017.

    Time frame: at Month 1, Month 6 and Month 12

07

Results

Posted Apr 14, 2020

Participant flow

74 pt. (25 \& 23 in reparixin continuous and intermittent infusion, and 26 in the pooled placebo) received the drug and were included in the safety population; 73 pt. (24, 23, 26) received both the study drug and the transplant and were included in the ITT. 1 started study drug but did not receive a kidney transplant, so was excluded from the ITT.

Participant flow — Overall Study
MilestoneReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Started252326
Completed222222
Not completed314
Withdrew: Transplantectomy213
Withdrew: Transplant cancelled post treat start100
Withdrew: Death001

Outcome measures

PrimaryCreatinine Clearance (CrCl) in the Immediate Post-transplant Period

CrCl was determined by two 60 minute urine collections, during the time intervals 1-3 and 10-12 hours of allograft reperfusion. Blood was withdrawn at the midpoint of each urine collection. CrCl at each timepoint was calculated according to the formula: creatinine clearance (mL/minutes) = urine creatinine (mmol/L) x urine volume (mL) / serum creatinine (mmol/L) x time of collection (minutes) An average was to be calculated from the two 60 minute values in each interval.

Time frame:
1-3 and 10-12 hours post allograft reperfusion
Reported as:
Mean · mL/min
Creatinine Clearance (CrCl) in the Immediate Post-transplant Period
mL/minReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
1-3 hours post-transplant5.11 ± 8.567.44 ± 12.816.30 ± 6.26
10-12 hours post-transplant9.66 ± 10.5214.45 ± 17.3910.75 ± 10.93
Statistical analysis
  • Reparixin Continuous Infusion vs Placebo Continuous/Intermittent Infusion · Other · p = 0.9076 · Difference between means: -0.275 · 95% CI -5.00 to 4.45
  • Reparixin Intermittent Infusion vs Placebo Continuous/Intermittent Infusion · Other · p = 0.3084 · Difference between means: 2.444 · 95% CI -2.32 to 7.21
  • Reparixin Continuous Infusion vs Reparixin Intermittent Infusion · Other · p = 0.2565 · Difference between means: -2.719 · 95% CI -7.47 to 2.03
  • Reparixin Continuous Infusion vs Placebo Continuous/Intermittent Infusion · Other · p = 0.9855 · Difference between means: -0.063 · 95% CI -6.91 to 6.79
  • Reparixin Intermittent Infusion vs Placebo Continuous/Intermittent Infusion · Other · p = 0.1934 · Difference between means: 4.519 · 95% CI -2.36 to 11.39
  • Reparixin Continuous Infusion vs Reparixin Intermittent Infusion · Other · p = 0.1797 · Difference between means: -4.582 · 95% CI -11.3 to 2.17
SecondaryRenal Function Tests - Serum Creatinine

Serum creatinine (SrCr) was measured daily from Day 1 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier; in patients undergoing dialysis, SrCr values were measured immediately before dialysis.

Time frame:
daily up to day 7 post-transplant or hospital discharge
Reported as:
Mean · mmol/L
Renal Function Tests - Serum Creatinine
mmol/LReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Infusion
Day 10.686 ± 0.1780.643 ± 0.2190.651 ± 0.202
Day 20.683 ± 0.2440.576 ± 0.2540.658 ± 0.278
0.Day 30.632 ± 0.3110.500 ± 0.2700.613 ± 0.317
Day 40.589 ± 0.3300.427 ± 0.2600.601 ± 0.360
Day 50.509 ± 0.2810.383 ± 0.2530.567 ± 0.367
Day 60.510 ± 0.3340.333 ± 0.2060.570 ± 0.407
Day 70.474 ± 0.3510.318 ± 0.2120.542 ± 0.411
SecondaryRenal Function Tests - Calculated Glomerular Filtration Rate

Calculated glomerular filtration rate (GFR) was measured daily from Day 1 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier; in patients undergoing dialysis, SrCr values were measured immediately before dialysis

Time frame:
from Day 1 up to 7 days post-transplant or up to hospital discharge
Reported as:
Mean · mL/min
Renal Function Tests - Calculated Glomerular Filtration Rate
mL/minReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Day 16.04 ± 2.998.03 ± 6.467.03 ± 3.48
Day 26.95 ± 5.0010.68 ± 8.618.74 ± 8.06
Day 310.99 ± 12.2614.86 ± 11.6713.15 ± 15.22
Day 413.90 ± 15.1519.64 ± 15.2815.79 ± 18.57
Day 517.97 ± 22.5323.91 ± 19.0218.61 ± 22.03
Day 620.46 ± 24.2426.64 ± 19.8120.75 ± 24.01
Day 722.42 ± 22.3528.06 ± 20.1022.70 ± 24.45
SecondaryRenal Function Tests - Urine Output

Urine output, measured in the interval from transplant to 8:00 of Day 1, and then daily from Day 2 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier

Time frame:
from Day 1 up to 7 days post-transplant or up to hospital discharge
Reported as:
Mean · mL
Renal Function Tests - Urine Output
mLReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Day 11615.9 ± 2082.71749.9 ± 2109.91925.3 ± 2214.1
Day 22242.7 ± 2236.82620.2 ± 2444.12844.5 ± 2861.2
Day 32321.1 ± 2087.82979.6 ± 2000.12904.0 ± 2468.3
Day 42409.8 ± 2043.22583.3 ± 1698.62939.4 ± 2585.0
Day 51958.2 ± 1609.22474.8 ± 1575.42035.4 ± 1816.7
Day 61795.8 ± 1206.22239.3 ± 1228.11994.8 ± 1688.5
Day 72072.3 ± 1240.92226.1 ± 1093.21805.1 ± 1390.9
SecondaryNumber of Patients Requiring Dialysis Within 7 Days Post-transplant

The number of patients who required dialysis within 7 days post-transplant was evaluated.

Time frame:
up to day 7 post-transplant
Reported as:
Count of participants · Participants
Number of Patients Requiring Dialysis Within 7 Days Post-transplant
ParticipantsReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Infusion
Yes776
No151518
Unknown212
SecondaryNumber of Days on Dialysis Before Resuming Kidney Function

the number of days on dialysis before resuming kidney function was evaluated.

Time frame:
up to Day 7 post-transplant
Reported as:
Mean · days
Number of Days on Dialysis Before Resuming Kidney Function
daysReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Number of Days on Dialysis Before Resuming Kidney Function2.5 ± 0.71.0 ± 0.02.0 ± 0.0
SecondaryNumber of Patients With Immediate, Slow and Delayed Graft Function

The number of patients who required dialysis within 7 days post-transplant was evaluated. Immediate graft function: SrCr ≤3 mg/dL on post operative day 5) Slow graft function: SrCr \>3 mg/dL dL on post operative day 5, no need of dialysis) Delayed graft function: Dialysis needed in the first week)

Time frame:
day 5 post-transplant
Reported as:
Count of participants · Participants
Number of Patients With Immediate, Slow and Delayed Graft Function
ParticipantsReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Immediate graft function6107
Slow graft function8511
Delayed graft function886
Unknown202
SecondaryDuration of Hospital Stay

The mean duration of hospital stay was evaluated.

Time frame:
first 30 days post-transplant
Reported as:
Mean · days
Duration of Hospital Stay
daysReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Duration of Hospital Stay14.6 ± 8.416.1 ± 7.613.3 ± 7.9
SecondaryMortality

Mortality in the first 30 days post-transplant was evaluated.

Time frame:
first 30 days post-transplant
Reported as:
Count of participants · Participants
Mortality
ParticipantsReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
No242325
Yes001
SecondarySerum Creatinine at Month 1, Month 6 and Month 12

Serum creatinine (SrCr) was measured at Month 1, Month 6 and Month 12.

Time frame:
at Month 1, Month 6 and Month 12
Reported as:
Mean · mmo/L
Serum Creatinine at Month 1, Month 6 and Month 12
mmo/LReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Month 10.252 ± 0.22500.169 ± 0.07770.186 ± 0.0890
Month 60.145 ± 0.06580.139 ± 0.04170.179 ± 0.1227
Month 120.150 ± 0.08790.150 ± 0.06180.227 ± 0.2578
SecondaryCalculated Serum Creatinine Clearance at Month 1, Month 6 and Month 12

Creatinine clearance (CrCl) is the volume of blood plasma cleared of creatinine per unit time. It is a rapid and cost-effective method for the measurement of renal function.

Time frame:
at Month 1, Month 6 and Month 12
Reported as:
Mean · mL/min
Calculated Serum Creatinine Clearance at Month 1, Month 6 and Month 12
mL/minReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Month 142.86 ± 22.5644.75 ± 16.2041.21 ± 14.23
Month 652.43 ± 18.1851.14 ± 12.5446.93 ± 16.65
Month 1253.48 ± 20.3951.10 ± 15.0741.74 ± 19.03
SecondaryAcute Rejection Episodes at Month 6 and Between Month 6 and Month 12

Acute rejection defined as an increase in serum creatinine level after exclusion of other causes of graft dysfunction, accompanied by a sudden decline in glomerular filtration rate and renal function and well-established diagnostic features on kidney allograft biopsy which can be either antibody-mediated and/or T cell-mediated and can occur at any time after transplant.

Time frame:
at Month 6 and between Month 6 and Month 12
Reported as:
Number · episodes
Acute Rejection Episodes at Month 6 and Between Month 6 and Month 12
episodesReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Month 6262
Between Month 6 and Month 12004
SecondaryPatient Survival Rate

Numbers of patients alive, dead, and lost to follow up are reported.

Time frame:
at Month 1, Month 6 and Month 12
Reported as:
Count of participants · Participants
Patient Survival Rate
ParticipantsReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Month 1 - Alive222222
Month 1 - Dead001
Month 1 - Lost to follow up213
Month 6 - Alive202221
Month 6 - Dead000
Month 6 - Lost to follow up201
Month 12 - Alive192121
Month 12 - Dead010
Month 12 - Lost to follow up100
SecondaryGraft Survival Rate

Graft failure was defined as the failure of graft function for any reason, ultimately requiring renal replacement therapy and/or retransplantation (United States Renal Data System \[USRDS\] 2017.

Time frame:
at Month 1, Month 6 and Month 12
Reported as:
Number · number of grafts
Graft Survival Rate
number of graftsReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
Month 1 - Graft functioning212222
Month 1 - Graft failed313
Month 6 - Graft functioning192220
Month 6 - Graft failed001
Month 12 - Graft functioning182020
Month 12 - Graft failed110

Adverse events

Collected over All AEs were reported up to 10 days or hospital discharge. Thereafter, only untoward events that the Investigator assessed as at least possibly related to the study drug were recorded. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reparixin Continuous Infusion0/25 (0%)12/25 (48%)24/25 (96%)
Reparixin Intermittent Infusion0/23 (0%)5/23 (21.7%)23/23 (100%)
Placebo Continuous/Intermittent Infusion1/26 (3.8%)9/26 (34.6%)25/26 (96.2%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
RENAL VEIN THROMBOSISRenal and urinary disorders1/250/233/26
METABOLIC ACIDOSISMetabolism and nutrition disorders2/250/230/26
RENAL TUBULAR NECROSISRenal and urinary disorders2/250/231/26
HYPOTENSIONVascular disorders2/250/230/26
RETROPERITONEAL HAEMORRHAGEVascular disorders2/250/230/26
IleusGastrointestinal disorders0/251/230/26
KIDNEY TRANSPLANT REJECTIONImmune system disorders0/251/231/26
URINARY ANASTOMOTIC LEAKInjury, poisoning and procedural complications0/251/230/26
URETERIC FISTULARenal and urinary disorders1/251/231/26
URETERAL NECROSISRenal and urinary disorders0/251/230/26
Most frequent other events
Showing 10 of 118
Most frequent other events
EventReparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent Infusion
ANAEMIABlood and lymphatic system disorders6/2510/2312/26
CONSTIPATIONGastrointestinal disorders8/255/236/26
RENAL TUBULAR NECROSISRenal and urinary disorders5/257/237/26
HYPOKALAEMIAMetabolism and nutrition disorders4/256/233/26
DIABETES MELLITUSMetabolism and nutrition disorders6/253/234/26
HYPOTENSIONVascular disorders6/255/233/26
URINARY TRACT INFECTIONInfections and infestations4/255/232/26
VOMITINGGastrointestinal disorders5/251/234/26
ACIDOSISMetabolism and nutrition disorders4/252/235/26
BLADDER SPASMRenal and urinary disorders4/252/231/26

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Reparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent InfusionTotal
<=18 years0000
Between 18 and 65 years25232674
>=65 years0000
Age, Continuous
Age, Continuous(years)Reparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent InfusionTotal
Mean54.4 ± 7.455.9 ± 6.351.4 ± 11.353.8 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Reparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent InfusionTotal
Female18131950
Male710724
Region of Enrollment
Region of Enrollment(participants)Reparixin Continuous InfusionReparixin Intermittent InfusionPlacebo Continuous/Intermittent InfusionTotal
France1091029
United States2248
Spain75416
Italy67821
08

Study locations

9 sites
  • Transplant Center, University of Minnesota Medical School
    Minneapolis, Minnesota 55455, United States
  • Division of Transplantation, Drexel University College of Medicine
    Philadelphia, Pennsylvania 19102, United States
  • Service de Nephrologie et Transplantation, Hopital Lapeyronie, Centre Hospitalier Universitaire Montpellier
    Montpellier, 34295 Cedex 5, France
  • Service de Transplantation et Soins Intensifs Nephrologiques, Hopital Necker
    Paris, 75743 Cedex 15, France
  • Divisione di Nefrologia e Dialisi, Ospedali Riuniti di Bergamo
    Bergamo, 24128, Italy
  • Divisione di Nefrologia e Dialisi, Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Università degli Studi di Padova, Clinica Chirurgica III
    Padova, 35128, Italy
  • Renal Transplant Unit, Hopital Clinic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Division of Nephrology, Institut Catala de la Salut, Ciutat Sanitaria i Universitaria de Bellvitge
    Barcelona, 08907, Spain
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2005 to primary completion in May 2008, 31 months.

Results were first posted in Apr 2020, 11 years 11 months after primary completion.

Of 18 phase 2 interventional studies under Reperfusion Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2005
First posted
Nov 3, 2005
StartActual
Oct 2005
Primary completionActual
May 2008
CompletionActual
Jun 2008
Results first posted
Apr 14, 2020
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00248040
Responsible party
Sponsor
First posted
Nov 3, 2005
Start date
Oct 2005
Primary completion
May 2008
Completion
Jun 2008
Results posted
Apr 14, 2020
Last update
Jan 10, 2024

Study contacts

Giuseppe Remuzzi, MD
principal investigator · A.O. Ospedale Papa Giovanni XXIII
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Reparixin

Start the discussion